Indian Journal of Pharmacology Home 

CORRESPONDENCE
[Download PDF]
Year : 2006  |  Volume : 38  |  Issue : 6  |  Page : 438-

Reply

SK Das, DM Vasudevan 
 Department of Biochemistry, Amrita Institute of Medical Sciences, Elamakkara P.O., Cochin-682 026, India

Correspondence Address:
S K Das
Department of Biochemistry, Amrita Institute of Medical Sciences, Elamakkara P.O., Cochin-682 026
India




How to cite this article:
Das S K, Vasudevan D M. Reply.Indian J Pharmacol 2006;38:438-438


How to cite this URL:
Das S K, Vasudevan D M. Reply. Indian J Pharmacol [serial online] 2006 [cited 2020 Feb 26 ];38:438-438
Available from: http://www.ijp-online.com/text.asp?2006/38/6/438/28218


Full Text

We sincerely appreciate the interest shown by the readers in our article entitled "Drugs and non-alcoholic steatohepatitis" (Indian J Pharmacol 2006;38:238-42). Non-alcoholic steatohepatitis (NASH) has been associated with obesity, diabetes, hypertriglyceridemia and hypertension. In addition, NASH has also been associated with hyperlipoproteinemia, jejunal bypass surgery, parenteral nutrition and drugs. In this article, we highlighted lists of drugs that are commonly used for the treatment of obesity, diabetes, hypertriglyceridemia and hypertension, irrespective of geographical barrier, and associated with hepatoxicity. We also tried to discuss briefly the mechanism of action of these drugs. A number of pharmacologic agents have been shown to be promising in the treatment of NASH, but they need to be studied further. In fact, a trial, utilizing troglitazone, had shown encouraging results, but because of reports of rare but serious hepatotoxicity, the drug has now been withdrawn from the market.[1] Therefore, awareness about these hazardous drugs is very important.

References

1Das SK, Mukherjee S, Vasudevan DM. Non-alcoholic fatty liver disease: An underrecognized cause with emerging importance. Curr Sci 2006;90:659-65.